The marketing authorisation for Optimark has been withdrawn at the request of the marketing authorisation holder.
Optimark : EPAR - Summary for the public (PDF/555.62 KB)
First published: 02/08/2007
Last updated: 16/06/2016
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Magnetic Resonance Imaging
|Anatomical therapeutic chemical (ATC) code||
Mallinckrodt Deutschland GmbH
|Date of issue of marketing authorisation valid throughout the European Union||
10/04/2017 Optimark - EMEA/H/C/000745 - T/0037
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
This medicinal product is for diagnostic use only.
Optimark is indicated for use with magnetic resonance imaging (MRI) of the central nervous system (CNS) and liver. It provides contrast enhancement and facilitates visualisation and helps with the characterisation of focal lesions and abnormal structures in the CNS and liver in patients with known or highly suspected pathology.